Did BGLC stock beat earnings estimates in the most recent quarter?
BIONEXUS GENE LAB CORP (BGLC) missed EPS estimates and missed revenue estimates in the most recent quarter.
NASDAQ:BGLC • US0906283066
Past quarterly earnings results for BIONEXUS GENE LAB CORP (BGLC), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | - | - | 2.544M | - | -3.29% | |||
| Q2 2025 | - | - | 2.26M | - | 14.47% | |||
| Q1 2025 | - | - | 2.137M | - | -10.28% | |||
| Q4 2024 | - | - | 2.524M | - | 11.03% | |||
| Q3 2024 | - | - | 2.63M | - | 3.00% | |||
| Q2 2024 | - | - | 1.975M | - | -23.17% | |||
| Q1 2024 | - | - | 2.382M | - | 0.08% | |||
| Q4 2023 | - | - | 2.273M | - | -19.96% | |||
| Q3 2023 | - | - | 2.554M | - | -1.02% | |||
| Q2 2023 | - | - | 2.57M | - | 3.21% | |||
| Q1 2023 | - | - | 2.38M | - | -21.45% | |||
| Q4 2022 | - | - | 2.84M | - | -12.62% | |||
| Q3 2022 | - | - | 2.58M | - | -27.93% | |||
| Q2 2022 | - | - | 2.49M | - | -19.42% | |||
| Q1 2022 | - | - | 3.03M | - | -12.17% | |||
| Q4 2021 | - | - | 3.25M | - | -71.39% | |||
| Q3 2021 | - | - | 3.58M | - | 15.86% | |||
| Q2 2021 | - | - | 3.09M | - | 180.91% | |||
| Q1 2021 | - | - | 3.45M | - | 12.38% | |||
| Q4 2020 | - | - | 11.36M | - | - | |||
| Q3 2020 | - | - | 3.09M | - | - | |||
| Q2 2020 | - | - | 1.1M | - | - | |||
| Q1 2020 | - | - | 3.07M | - | - |
Notes
BIONEXUS GENE LAB CORP (BGLC) missed EPS estimates and missed revenue estimates in the most recent quarter.